The TetraVecta™ System: Optimisation & Exemplification of OXB’s Next Generation Lentiviral Vector
What’s Upstream of Downstream Matters: Utilising High-Efficiency Secreted Nuclease (SecNuc™ Enzyme) and Transgene Repression (TRiP System™) to Improve rAAV Production
Development and Scale Up of Next Generation Lentiviral Vector Batch Process Demonstrating Increased Productivity and Enhanced Purity
Increasing AAV Productivity Upstream Process Optimization for a Robust, Plug-and-Play Platform
Enhancing Titers of Therapeutic Lentiviral Vectors using PKC Agonists
The 3 Rs Of Replication-Competent Lentivirus (RCL) Formation Risk: Real, Rare, or Artificial?
Optimising the Production of the 4th Generation Lentiviral Vector (LV) TetraVecta™ System: Towards Plug-and-Play LV Manufacturing
The Impact of Individual Helper Genes on AAV Productivity
Evaluation of Salt-Tolerant Endonucleases for Lentiviral Vector Purification
Enhancing Upstream Processes for High-Yield, High-Quality AAV Vector Production Using a Novel In-House Cell Line
Diving Deeper: Using a SYBR Gold Capsid Ejection Assay as an Orthogonal Method of Measuring Potency and VP1 Deamidation in AAV9 Drug Product Samples
Accelerate Time to Clinic: A Platform and Analytics Approach
